Advances in Cancer Therapy


February 1, 2001
394 Pages - SKU: KLI25
License type:
The World Market for Pain Management Drugs and Devices
5/20/2013 | published by: Kalorama Information
The World Market for Pain Management Drugs and Devices encompasses a wide variety of products that treat and ease pain. The field of pain management is currently experiencing a busy and interesting period; and  |  read more...
$3,500.00
The World Market for Cancer Diagnostics, 5th Edition: Precision and Personalized Testing Arrives
5/8/2013 | published by: Kalorama Information
The World Market for Cancer Diagnostics, 5th Edition: Precision and Personalized Testing Arrives Cancer testing is maturing from personalized medicine to precision medicine, where protein and molecular biomarkers are essential for precise diagnosis,  |  read more...
$4,500.00
Bladder Cancer – Executive Market Summary 2013
5/20/2013 | published by: Timely Data Resources, Inc.
The Bladder Cancer Executive Market Summary 2013 provides an overview of the disease and related conditions, with incidence, prevalence, and mortality numbers and percentages for major countries worldwide, information on diagnosis, and an overview of  |  read more...
$950.00
PharmaPoint: Chronic Myeloid Leukemia (CML) - Current and Future Players
5/15/2013 | published by: GlobalData
PharmaPoint: Chronic Myeloid Leukemia (CML) - Current and Future Players Summary GlobalData has released its pharma report, “PharmaPoint: Chronic Myeloid Leukemia (CML) - Current and Future Players”. The report is a vital source of up-to-date information with  |  read more...
$2,995.00
Gleevec (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022
5/15/2013 | published by: GlobalData
Gleevec (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Gleevec (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022”. Chronic myeloid leukemia (CML) is  |  read more...
$3,495.00
Sprycel (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022
5/15/2013 | published by: GlobalData
Sprycel (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Sprycel (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022”. Chronic myeloid leukemia (CML) is  |  read more...
$3,495.00
Tasigna (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022
5/15/2013 | published by: GlobalData
Tasigna (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Tasigna (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022”. Chronic myeloid leukemia (CML) is  |  read more...
$3,495.00
Bosulif (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022
5/15/2013 | published by: GlobalData
Bosulif (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Bosulif (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022”. Chronic myeloid leukemia (CML) is  |  read more...
$3,495.00
Iclusig (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022
5/15/2013 | published by: GlobalData
Iclusig (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Iclusig (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022”. Chronic myeloid leukemia (CML) is  |  read more...
$3,495.00
Colorectal Cancer – Executive Market Summary 2013
5/20/2013 | published by: Timely Data Resources, Inc.
The Colorectal Cancer Executive Market Summary 2013 provides an overview of the disease and related conditions, with incidence, prevalence and mortality numbers and percentages for major countries worldwide, information on diagnosis, staging, and prognosis, and  |  read more...
$950.00